All posts
Clinical
Draft

How GLP-1 prescribing works in 2026: a complete guide for med spa owners

June 2026 · 8 min read

GLP-1 medications went mainstream faster than most clinics could build the workflow around them. Here is how prescribing actually works in 2026 — from who qualifies to how doses are escalated — without the hype.


GLP-1 receptor agonists — semaglutide and tirzepatide — have become the backbone of modern medical weight management. For a med spa or clinic adding a program, the hard part is not the medication; it is the workflow around it: deciding who qualifies, escalating doses safely, and keeping patients in follow-up.

Who qualifies

Eligibility for weight management generally starts at a BMI of 30 or above, or 27+ with a weight-related condition such as hypertension or type 2 diabetes. Pregnancy, a personal or family history of medullary thyroid carcinoma, and a few other conditions are absolute contraindications.

Eligibility is a ruleset, not a vibe. A defensible program encodes BMI thresholds, contraindications, and disqualifying answers into a structured intake — so the same standard is applied to every patient, and the edge cases route to a provider for review.

How titration works

GLP-1s are started low and increased gradually to limit gastrointestinal side effects. Semaglutide typically begins at 0.25 mg weekly and steps up roughly every four weeks; tirzepatide starts at 2.5 mg on a similar cadence. The schedule is not a race — patients who tolerate a dose poorly hold or step back rather than push ahead.

  1. Start at the lowest dose and hold for the protocol interval.
  2. Step up only when the current dose is tolerated.
  3. Slow down or pause for significant nausea or GI symptoms.
  4. Document tolerance at each step — it is the basis for the next decision.

The visit flow

A typical program runs: structured intake → automated eligibility screen → provider review of anything flagged → prescription with a titration plan → pharmacy fulfillment → scheduled follow-up and refills. The clinician owns every clinical decision; software just makes the path repeatable and auditable.

The clinics that succeed treat GLP-1 as a longitudinal program, not a one-time script.

See the workflow end to end

Plexus runs intake, eligibility, prescribing, and follow-up as one compliant flow under your brand.

This article is for general educational purposes and is not medical advice. Clinical decisions should be made by a licensed provider for the individual patient.